WASHINGTON — The combination of ipilimumab (Yervoy) and nivolumab (Opdivo) can be used to treat intermediate- to poor-risk patients with previously untreated renal cell carcinoma, the FDA said Monday.
Read More: https://www.medpagetoday.com/hematologyoncology/othercancers/72376
